Kacen, A. et al. Post-translational modifications reshape the antigenic landscape of the MHC I immunopeptidome in tumors. Nat. Biotechnol. 41, 239–251 (2023).
Kelly, S. D., Allas, M. J., Goodridge, L. D., Lowary, T. L. & Whitfield, C. Structure, biosynthesis and regulation of the T1 antigen, a phase-variable surface polysaccharide conserved in many Salmonella serovars. Nat. Commun. 15, 6504 (2024).
Teplensky, M. H. et al. Multi-antigen spherical nucleic acid cancer vaccines. Nat. Biomed. Eng. 7, 911–927 (2023).
Ando, Y. et al. Using tumor marker gene variants to improve the diagnostic accuracy of DUPAN-2 and carbohydrate antigen 19-9 for pancreatic cancer. J. Clin. Oncol. 42, 2196–2206 (2024).
Liang, X., Cheng, H., Liu, C. & Liu, G. Antigen self-presenting nanovaccine for cancer immunotherapy. Sci. Bull. 67, 1611–1613 (2022).
Yang, J., Chen, Y., Jing, Y., Green, M. R. & Han, L. Advancing CAR T cell therapy through the use of multidimensional omics data. Nat. Rev. Clin. Oncol. 20, 211–228 (2023).
Xie, N. et al. Neoantigens: promising targets for cancer therapy. Signal Transduct. Target. Ther. 8, 9 (2023).
Ding, Q. et al. Signaling pathways in rheumatoid arthritis: implications for targeted therapy. Signal Transduct. Target. Ther. 8, 68 (2023).
Zhong, Q. et al. Protein posttranslational modifications in health and diseases: functions, regulatory mechanisms, and therapeutic implications. MedComm 4, e261 (2023).
Curran, A. M. et al. Citrullination modulates antigen processing and presentation by revealing cryptic epitopes in rheumatoid arthritis. Nat. Commun. 14, 1061 (2023).
Alivernini, S., Firestein, G. S. & McInnes, I. B. The pathogenesis of rheumatoid arthritis. Immunity 55, 2255–2270 (2022).
Maggi, J. et al. Isolation of HLA-DR-naturally presented peptides identifies T-cell epitopes for rheumatoid arthritis. Ann. Rheum. Dis. 81, 1096–1105 (2022).
Toes, R. & Pisetsky, D. S. Pathogenic effector functions of ACPA: where do we stand? Ann. Rheum. Dis. 78, 716–721 (2019).
Ge, C. et al. Structural basis of cross-reactivity of anti-citrullinated protein antibodies. Arthritis Rheumatol. 71, 210–221 (2019).
Steen, J. et al. Recognition of amino acid motifs, rather than specific proteins, by human plasma cell-derived monoclonal antibodies to posttranslationally modified proteins in rheumatoid arthritis. Arthritis Rheumatol. 71, 196–209 (2019).
Lewallen, D. M. et al. Chemical proteomic platform to identify citrullinated proteins. ACS Chem. Biol. 10, 2520–2528 (2015).
Tilvawala, R. et al. The rheumatoid arthritis-associated citrullinome. Cell Chem. Biol. 25, 691–704.e696 (2018).
Juarez, M. et al. Identification of novel antiacetylated vimentin antibodies in patients with early inflammatory arthritis. Ann. Rheum. Dis. 75, 1099–1107 (2016).
Scherer, H. U., van der Woude, D. & Toes, R. E. M. From risk to chronicity: evolution of autoreactive B cell and antibody responses in rheumatoid arthritis. Nat. Rev. Rheumatol. 18, 371–383 (2022).
Suwannalai, P. et al. Low-avidity anticitrullinated protein antibodies (ACPA) are associated with a higher rate of joint destruction in rheumatoid arthritis. Ann. Rheum. Dis. 73, 270–276 (2014).
Bondt, A. et al. ACPA IgG galactosylation associates with disease activity in pregnant patients with rheumatoid arthritis. Ann. Rheum. Dis. 77, 1130–1136 (2018).
Willemze, A., Trouw, L. A., Toes, R. E. & Huizinga, T. W. The influence of ACPA status and characteristics on the course of RA. Nat. Rev. Rheumatol. 8, 144–152 (2012).
van der Woude, D. & Toes, R. E. M. Immune response to post-translationally modified proteins in rheumatoid arthritis: what makes it special?. Ann. Rheum. Dis. 83, 838–846 (2024).
Gerlag, D. M. et al. EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the study group for risk factors for rheumatoid arthritis. Ann. Rheum. Dis. 71, 638–641 (2012).
He, S. et al. A longitudinal cohort study uncovers plasma protein biomarkers predating clinical onset and treatment response of rheumatoid arthritis. Nat. Commun. 16, 6692 (2025).
Mondal, S. & Thompson, P. R. Protein arginine deiminases (PADs): biochemistry and chemical biology of protein citrullination. Acc. Chem. Res. 52, 818–832 (2019).
Assohou-Luty, C. et al. The human peptidylarginine deiminases type 2 and type 4 have distinct substrate specificities. Biochim. Biophys. Acta. 1844, 829–836 (2014).
Gong, Y. et al. Acetylation profiling by Iseq-Kac reveals insights into HSC aging and lineage decision. Nat. Chem. Biol. 21, 1675–1687 (2025).
Rebak, A. S. et al. A quantitative and site-specific atlas of the citrullinome reveals widespread existence of citrullination and insights into PADI4 substrates. Nat. Struct. Mol. Biol. 31, 977–995 (2024).
Clancy, K. W., Weerapana, E. & Thompson, P. R. Detection and identification of protein citrullination in complex biological systems. Curr. Opin. Chem. Biol. 30, 1–6 (2016).
Lee, C. Y. et al. Mining the human tissue proteome for protein citrullination. Mol. Cell. Proteom. 17, 1378–1391 (2018).
Hensen, S. M. & Pruijn, G. J. Methods for the detection of peptidylarginine deiminase (PAD) activity and protein citrullination. Mol. Cell. Proteom. 13, 388–396 (2014).
Buda, M., Maki, A. & Mazurowski, M. A. A systematic study of the class imbalance problem in convolutional neural networks. Neural Netw. 106, 249–259 (2018).
Murata, K. et al. Hypoxia-sensitive COMMD1 integrates signaling and cellular metabolism in human macrophages and suppresses osteoclastogenesis. Immunity 47, 66–79.e65 (2017).
Lee, S. et al. Identification of MYH9 as a key regulator for synoviocyte migration and invasion through secretome profiling. Ann. Rheum. Dis. 82, 1035–1048 (2023).
Zhao, X. et al. Circulating immune complexes contain citrullinated fibrinogen in rheumatoid arthritis. Arthritis Res. Ther. 10, R94 (2008).
Iwamoto, N. et al. Osteogenic differentiation of fibroblast-like synovial cells in rheumatoid arthritis is induced by microRNA-218 through a ROBO/Slit pathway. Arthritis Res. Ther. 20, 189 (2018).
Muller, S. & Radic, M. Citrullinated autoantigens: from diagnostic markers to pathogenetic mechanisms. Clin. Rev. Allergy Immunol. 49, 232–239 (2015).
Sturfelt, G. & Truedsson, L. Complement in the immunopathogenesis of rheumatic disease. Nat. Rev. Rheumatol. 8, 458–468 (2012).
Tran, L. S. et al. ER O-glycosylation in synovial fibroblasts drives cartilage degradation. Nat. Commun. 16, 2535 (2025).
Olumuyiwa-Akeredolu, O. O., Page, M. J., Soma, P. & Pretorius, E. Platelets: emerging facilitators of cellular crosstalk in rheumatoid arthritis. Nat. Rev. Rheumatol. 15, 237–248 (2019).
Niehaus, J. K., Taylor-Blake, B., Loo, L., Simon, J. M. & Zylka, M. J. Spinal macrophages resolve nociceptive hypersensitivity after peripheral injury. Neuron 109, 1274–1282.e1276 (2021).
Ummarino, D. Rheumatoid arthritis: ACPA status influences RA development. Nat. Rev. Rheumatol. 13, 450 (2017).
Pertsinidou, E. et al. In early rheumatoid arthritis, anticitrullinated peptide antibodies associate with low number of affected joints and rheumatoid factor associates with systemic inflammation. Ann. Rheum. Dis. 83, 277–287 (2024).
Kastbom, A. et al. Changes in anti-citrullinated protein antibody isotype levels in relation to disease activity and response to treatment in early rheumatoid arthritis. Clin. Exp. Immunol. 194, 391–399 (2018).
Takeuchi, T. et al. High titers of both rheumatoid factor and anti-CCP antibodies at baseline in patients with rheumatoid arthritis are associated with increased circulating baseline TNF level, low drug levels, and reduced clinical responses: a post hoc analysis of the RISING study. Arthritis Res. Ther. 19, 194 (2017).
Wells, G. et al. Validation of the 28-joint disease activity score (DAS28) and European league against rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann. Rheum. Dis. 68, 954–960 (2009).
Smolen, J. S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann. Rheum. Dis. 69, 964–975 (2010).
Megahed, F. M. et al. The class imbalance problem. Nat. Methods 18, 1270–1272 (2021).
Muthukrishnan, R. & Rohini, R. in 2016 IEEE International Conference on Advances in Computer Applications (ICACA) 18–20 (IEEE, 2016).
Zhu, X. W., Xin, Y. J. & Ge, H. L. Recursive random forests enable better predictive performance and model interpretation than variable selection by LASSO. J. Chem. Inf. Model. 55, 736–746 (2015).
Shieh, M.-D. & Yang, C.-C. Multiclass SVM-RFE for product form feature selection. Expert Syst. Appl. 35, 531–541 (2008).
Guan, S. et al. Identifying potential targets for preventing cancer progression through the PLA2G1B recombinant protein using bioinformatics and machine learning methods. Int. J. Biol. Macromol. 276, 133918 (2024).
Efthimiou, O. et al. Developing clinical prediction models: a step-by-step guide. BMJ 386, e078276 (2024).
Sahlström, P. et al. Different hierarchies of anti-modified protein autoantibody reactivities in rheumatoid arthritis. Arthritis Rheumatol. 72, 1643–1657 (2020).
Zheng, Z. et al. Disordered antigens and epitope overlap between anti-citrullinated protein antibodies and rheumatoid factor in rheumatoid arthritis. Arthritis Rheumatol. 72, 262–272 (2020).
Lo, K. C. et al. Comprehensive profiling of the rheumatoid arthritis antibody repertoire. Arthritis Rheumatol. 72, 242–250 (2020).
Thandapani, P., O’Connor, T. R., Bailey, T. L. & Richard, S. Defining the RGG/RG motif. Mol. Cell 50, 613–623 (2013).
Ali, S. M. et al. Baseline serum NTx levels are prognostic in metastatic breast cancer patients with bone-only metastasis. Ann. Oncol. 15, 455–459 (2004).
Fert-Bober, J., Darrah, E. & Andrade, F. Insights into the study and origin of the citrullinome in rheumatoid arthritis. Immunol. Rev. 294, 133–147 (2020).
Kokkonen, H. et al. Antibodies of IgG, IgA and IgM isotypes against cyclic citrullinated peptide precede the development of rheumatoid arthritis. Arthritis Res. Ther. 13, R13 (2011).
Ten Brinck, R. M., Toes, R. E. M. & van der Helm-van Mil, A. H. M. Inflammation functions as a key mediator in the link between ACPA and erosion development: an association study in clinically suspect arthralgia. Arthritis Res. Ther. 20, 89 (2018).
van Delft, M. A. M. & Huizinga, T. W. J. An overview of autoantibodies in rheumatoid arthritis. J. Autoimmun. 110, 102392 (2020).
Yu, K. & Proost, P. Insights into peptidylarginine deiminase expression and citrullination pathways. Trends Cell Biol. 32, 746–761 (2022).
Wouters, F. et al. Determining in which pre-arthritis stage HLA-shared epitope alleles and smoking exert their effect on the development of rheumatoid arthritis. Ann. Rheum. Dis. 81, 48–55 (2022).
Di Matteo, A., Bathon, J. M. & Emery, P. Rheumatoid arthritis. Lancet 402, 2019–2033 (2023).
Sparks, J. A. & Costenbader, K. H. Rheumatoid arthritis in 2017: protective dietary and hormonal factors brought to light. Nat. Rev. Rheumatol. 14, 71–72 (2018).
Smolen, J. S., Aletaha, D. & McInnes, I. B. Rheumatoid arthritis. Lancet 388, 2023–2038 (2016).
Jiang, L. et al. A high-fiber diet synergizes with Prevotella copri and exacerbates rheumatoid arthritis. Cell. Mol. Immunol. 19, 1414–1424 (2022).
Trocmé, C. et al. Apolipoprotein A-I and platelet factor 4 are biomarkers for infliximab response in rheumatoid arthritis. Ann. Rheum. Dis. 68, 1328–1333 (2009).
Cho, A. et al. A multi-biomarker panel for predicting tocilizumab response in rheumatoid arthritis patients. Transl. Res. 273, 23–31 (2024).
Smolen, J. S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann. Rheum. Dis. 79, 685–699 (2020).
Zhang, T. et al. Serum proteomics analysis of biomarkers for evaluating clinical response to MTX/IGU therapy in early rheumatoid arthritis. Mol. Immunol. 153, 119–125 (2023).
Ponchel, F. et al. An immunological biomarker to predict MTX response in early RA. Ann. Rheum. Dis. 73, 2047–2053 (2014).
Maciejewski, M. et al. Prediction of response of methotrexate in patients with rheumatoid arthritis using serum lipidomics. Sci. Rep. 11, 7266 (2021).
Owen, S. A. et al. Genetic polymorphisms in key methotrexate pathway genes are associated with response to treatment in rheumatoid arthritis patients. Pharmacogenomics J. 13, 227–234 (2013).
Liu, T., Shi, K. & Li, W. Deep learning methods improve linear B-cell epitope prediction. BioData Min. 13, 1 (2020).
Shashkova, T. I. et al. SEMA: antigen B-cell conformational epitope prediction using deep transfer learning. Front. Immunol. 13, 960985 (2022).
Ju, Z. & Wang, S. Y. Prediction of citrullination sites by incorporating k-spaced amino acid pairs into Chou’s general pseudo amino acid composition. Gene 664, 78–83 (2018).
Liu, Y., Li, A., Zhao, X. M. & Wang, M. DeepTL-Ubi: a novel deep transfer learning method for effectively predicting ubiquitination sites of multiple species. Methods 192, 103–111 (2021).
Yang, H., Wang, M., Liu, X., Zhao, X. M. & Li, A. PhosIDN: an integrated deep neural network for improving protein phosphorylation site prediction by combining sequence and protein-protein interaction information. Bioinformatics 37, 4668–4676 (2021).
Wang, H., Zhao, H., Yan, Z., Zhao, J. & Han, J. MDCAN-Lys: a model for predicting succinylation sites based on multilane dense convolutional attention network. Biomolecules 11, 872 (2021).
Meng, L. et al. TransPTM: a transformer-based model for non-histone acetylation site prediction. Brief. Bioinform. 25, 3 (2024).
Luo, F., Wang, M., Liu, Y., Zhao, X. M. & Li, A. DeepPhos: prediction of protein phosphorylation sites with deep learning. Bioinformatics 35, 2766–2773 (2019).
Deznabi, I., Arabaci, B., Koyutürk, M. & Tastan, O. DeepKinZero: zero-shot learning for predicting kinase-phosphosite associations involving understudied kinases. Bioinformatics 36, 3652–3661 (2020).
Parvez, A., Ali, S. D., Tayara, H. & Chong, K. T. Stacking based ensemble learning framework for identification of nitrotyrosine sites. Comput. Biol. Med. 183, 109200 (2024).
Anashkina, A. A. et al. A novel approach for predicting protein S-glutathionylation. BMC Bioinform. 21, 282 (2020).
Guo, Y. et al. GPS-PBS: a deep learning framework to predict phosphorylation sites that specifically interact with phosphoprotein-binding domains. Cells 9, 1266 (2020).
Ahmed, S., Kabir, M., Arif, M., Khan, Z. U. & Yu, D. J. DeepPPSite: a deep learning-based model for analysis and prediction of phosphorylation sites using efficient sequence information. Anal. Biochem. 612, 113955 (2021).
Tilvawala, R. et al. The role of SERPIN citrullination in thrombosis. Cell Chem. Biol. 28, 1728–1739.e1725 (2021).
Sun, L. et al. A new unconventional HLA-A2-restricted epitope from HBV core protein elicits antiviral cytotoxic T lymphocytes. Protein Cell 5, 317–327 (2014).
Lagattuta, K. A. et al. Repertoire analyses reveal T cell antigen receptor sequence features that influence T cell fate. Nat. Immunol. 23, 446–457 (2022).
Sakuma, S. et al. FK506 potently inhibits T cell activation induced TNF-alpha and IL-1beta production in vitro by human peripheral blood mononuclear cells. Br. J. Pharmacol. 130, 1655–1663 (2000).
Sanchez-Trincado, J. L., Gomez-Perosanz, M. & Reche, P. A. Fundamentals and methods for T- and B-cell epitope prediction. J. Immunol. Res. 2017, 2680160 (2017).
Hao, G. et al. Neutral loss of isocyanic acid in peptide CID spectra: a novel diagnostic marker for mass spectrometric identification of protein citrullination. J. Am. Soc. Mass Spectrom. 20, 723–727 (2009).
Chaerkady, R. et al. Characterization of citrullination sites in neutrophils and mast cells activated by ionomycin via integration of mass spectrometry and machine learning. J. Proteome Res. 20, 3150–3164 (2021).
Sonnett, M., Yeung, E. & Wühr, M. Accurate, sensitive, and precise multiplexed proteomics using the complement reporter ion cluster. Anal. Chem. 90, 5032–5039 (2018).
Hu, M. et al. Low-input, deep learning platform for citrullinated peptide identification, autoantigen discovery, and rheumatoid arthritis treatment stratification. iProX https://www.iprox.cn//page/project.html?id=IPX0009393000 (2025).
He, S. et al. A longitudinal cohort study uncovers plasma protein biomarkers predating clinical onset and treatment response of rheumatoid arthritis. iProX https://www.iprox.cn//page/project.html?id=IPX0005696000 (2025).